F. Comert Onder Et Al. , "Target-Driven Design of a Coumarinyl Chalcone Scaffold Based Novel EF2 Kinase Inhibitor Suppresses Breast Cancer Growth in Vivo," ACS Pharmacology and Translational Science , vol.4, no.2, pp.926-940, 2021
Comert Onder, F. Et Al. 2021. Target-Driven Design of a Coumarinyl Chalcone Scaffold Based Novel EF2 Kinase Inhibitor Suppresses Breast Cancer Growth in Vivo. ACS Pharmacology and Translational Science , vol.4, no.2 , 926-940.
Comert Onder, F., Kahraman, N., Bellur Atici, E., Cagir, A., Kandemir, H., Tatar, G., ... Taskin Tok, T.(2021). Target-Driven Design of a Coumarinyl Chalcone Scaffold Based Novel EF2 Kinase Inhibitor Suppresses Breast Cancer Growth in Vivo. ACS Pharmacology and Translational Science , vol.4, no.2, 926-940.
Comert Onder, FERAH Et Al. "Target-Driven Design of a Coumarinyl Chalcone Scaffold Based Novel EF2 Kinase Inhibitor Suppresses Breast Cancer Growth in Vivo," ACS Pharmacology and Translational Science , vol.4, no.2, 926-940, 2021
Comert Onder, FERAH C. Et Al. "Target-Driven Design of a Coumarinyl Chalcone Scaffold Based Novel EF2 Kinase Inhibitor Suppresses Breast Cancer Growth in Vivo." ACS Pharmacology and Translational Science , vol.4, no.2, pp.926-940, 2021
Comert Onder, F. Et Al. (2021) . "Target-Driven Design of a Coumarinyl Chalcone Scaffold Based Novel EF2 Kinase Inhibitor Suppresses Breast Cancer Growth in Vivo." ACS Pharmacology and Translational Science , vol.4, no.2, pp.926-940.
@article{article, author={FERAH CÖMERT ÖNDER Et Al. }, title={Target-Driven Design of a Coumarinyl Chalcone Scaffold Based Novel EF2 Kinase Inhibitor Suppresses Breast Cancer Growth in Vivo}, journal={ACS Pharmacology and Translational Science}, year=2021, pages={926-940} }